Incyte Corporation (INCY)

82.74
+0.43(+0.52%)
After Hours
82.74
0.00(0.00%)
- Real-time Data
  • Volume:
    1,113,248
  • Bid/Ask:
    81.75/83.22
  • Day's Range:
    82.12 - 84.26

INCY Overview

Prev. Close
82.31
Day's Range
82.12 - 84.26
Revenue
2.7B
Open
82.49
52 wk Range
75.52 - 110.32
EPS
2.17
Volume
1,113,248
Market Cap
18.2B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
1,251,988
P/E Ratio
38.09
Beta
0.8
1-Year Change
-14.23%
Shares Outstanding
219,923,477
Next Earnings Date
Aug 03, 2021
What is your sentiment on Incyte Corporation?
or
Market is currently closed. Voting is open during market hours.

Incyte Corporation News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyNeutralSellSell
Technical IndicatorsNeutralStrong BuyBuyStrong SellStrong Sell
SummaryNeutralStrong BuyNeutralStrong SellStrong Sell

Incyte Corporation Company Profile

Incyte Corporation Company Profile

Employees
1773

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Read More
  • Google play Khmer🌟
    0
    • Why is this guy down?
      1
      • What is going on this stock? It has been dipping with no limit?!
        1
        • beat Earnings, why down?
          3
          • Turkish biotechnology company produces RTALB diagnostic kit. Its products are in demand in 15 countries. The company has exported more than 2 million kits in the past month.
            2
            • This is why the stock lost 44% for the year? Who said $175?
              1
              • goes to 50...hmm
                1
                • Papa Putin said so?
                  2
              • This stock is conservatively worth $105. I wouldn't be surprised if its closer to $175 than $100 by the end of the yr.
                2
                • Also, one of the finest stock research letters (Oxford Communique) loved it at $100 and deemed it one of their Ten-Bagger portfolio stocks. The Oxford Club knows what they're talking about too.
                  1
                • Yeah, totally.
                  1
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.